ArticleJournal of neurology2016
Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
Article in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Does the Use of Intravenous Immunoglobulin Improve Clinical Outcomes in Adults With Autoimmune Encephalitis? A Systematic Review.Brain and behavior · 2025Pooled it
- Seizure outcome-related factors in autoimmune encephalitis: A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis.Frontiers in neurology · 2019Pooled it
- Seizure characteristics and neurological outcomes in pediatric anti-NMDAR encephalitis: a cohort study from Southern China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Elevated CHI3L1 as a Potential Biomarker of Cognitive Dysfunction in Anti-NMDAR Encephalitis: Evidence From Clinical Results and Mice Model.CNS neuroscience & therapeutics · 2026Article
- Case Report: Surgical resection of ovarian teratoma in anti-NMDAR encephalitis complicated by severe pneumonia.Frontiers in oncology · 2025Article
- Analysis of characteristics of movement disorders in patients with anti-N-methyl-D-aspartate receptor encephalitis.Frontiers in neurology · 2024Article
- Movement disorders in autoimmune encephalitis: an update.Journal of neurology · 2023Review
- Typical metabolic pattern ofBMC neuroscience · 2023Article
- Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis-A Systematic Review.Biomedicines · 2023Review
- Clinical and MRI differential analysis of autoimmune encephalitis and viral encephalitis.Journal of Taibah University Medical Sciences · 2023Article
- Temporal transformer-spatial graph convolutional network: an intelligent classification model for anti N-methyl-D-aspartate receptor encephalitis based on electroencephalogram signal.Frontiers in neuroscience · 2023Article
- Antibody Therapies in Autoimmune Encephalitis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- External Assessment of the Anti-N-Methyl-D-Aspartate Receptor Encephalitis One-Year Functional Status Score in Chinese Pediatric Patients.Frontiers in immunology · 2022Article
- High Dose Steroids as First-Line Treatment Increased the Risk of In-Hospital Infections in Patients With Anti-NMDAR Encephalitis.Frontiers in immunology · 2021Article
- Thyroid Function and Anti-thyroid Antibodies in Pediatric Anti-NMDAR Encephalitis.Frontiers in neurology · 2021Article
- Delta brush variant: A novel ictal EEG pattern in anti-NMDAR encephalitis.Epilepsia open · 2020Article
- Risk factors for pneumonia in patients with anti-NMDA receptor encephalitis: A single-center retrospective study.Medicine · 2020Article
- Clinical Features, Treatment, and Outcomes Among Chinese Children With Anti-methyl-D-aspartate Receptor (Anti-NMDAR) Encephalitis.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-Methyl-D-Aspartate receptor (NMDAR) encephalitis is an acute neurological disorder affecting children and adults. We aimed to compare the clinical characteristics, treatments, and outcomes between children and adults with anti-NMDAR encephalitis and to assess the probable risk factors. In this observational study, patients who tested positive for anti-NMDAR antibody in the cerebrospinal fluid were enrolled. The patients were divided into children and adults group on the basis of age (whether <16 or not). Clinical outcomes were assessed at onset, 1, 3, 6, 9, and 12 months after the patients received treatment and were scored based on whether they required hospitalization and intensive care. A total of 15 children and 14 adults were examined. The adults more likely manifested status epilepticus, central hypoventilation, and pneumonia but less likely exhibited movement disorder than the children did. All of the patients were subjected to corticosteroid treatment, 11 children and 9 adults were treated with intravenous immunoglobulin, and only the adults received plasma exchange or cyclophosphamide. The children recovered faster than the adults, especially in the first 6 months. Risk factors included age, status epilepticus, changes in consciousness, central hypoventilation, and pneumonia. Adults exhibit worse outcomes than children mostly because of status epilepticus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.